Using metadata analysis of clinical cohorts, reported datasets and TCGA patient data extraction, we identified Spp1 as a particularly promising target, since the high expression of this gene in breast cancer patients is coupled to poor patient survival and metastasis. This evidence concerns the gene SPP1 and breast cancer.